• 1
    Dye C., Scheele S., Dolin P., Pathania V., Raviglione M.C. (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. J Amm Med Assoc; 282:677686.
  • 2
    Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., Dye C. (2003) Tuberculosis. Lancet;362:887899.
  • 3
    WHO. (2006) Tuberculosis Facts. In: Tuberculosis Facts.
  • 4
    WHO. (2004) Tuberculosis Fact Sheet. In: Tuberculosis Fact Sheet.
  • 5
    Guerrin-Tran E., Thiolet J.M., Rousseau C., Henry S., Poirier C., Che D. et al. (2006) An evaluation of data quality in a network for surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs in Ile-de-France region-2001–2002. Eur J Epidemiol;21:783785.
  • 6
    Somoskovi A., Parsons L.M., Salfinger M. (2001) The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res;2:164168.
  • 7
    Saquib M., Gupta M.K., Sagar R., Prabhakar Y.S., Shaw A.K., Kumar R. et al. (2007) C-3 alkyl/arylalkyl-2,3-dideoxyhex-2-enopyranosides as antitubercular agents: synthesis, biological evaluation, and QSAR study. J Med Chem;50:29422950.
  • 8
    Pilheu J.A. (1998) Tuberculosis 2000: problems and solutions. Int J Tuberc Lung Dis;2:696703.
  • 9
    Espinal M.A. (2003) The global situation of MDR-TB. Tuberculosis (Edinb);83:4451.
  • 10
    Peloquin C.A., Berning S.E. (1994) Infection caused by Mycobacterium tuberculosis. Ann Pharmacother;28:7284.
  • 11
    Murray J.F. (1998) Tuberculosis and HIV infection: a global perspective. Respiration;65:335342.
  • 12
    Gordin F.M., Nelson E.T., Matts J.P., Cohn D.L., Ernst J., Benator D. et al. (1996) The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med;154:14781483.
  • 13
    Moss A.R., Alland D., Telzak E., Hewlett D. Jr, Sharp V., Chiliade P. et al. (1997) A city-wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis;1:115121.
  • 14
    Maher D., Raviglione M. (2005) Global epidemiology of tuberculosis. Clin Chest Med;26:167182, v.
  • 15
    Frieden T.R., Munsiff S.S. (2005) The DOTS strategy for controlling the global tuberculosis epidemic. Clin Chest Med;26:197205.
  • 16
    No authors listed (2006) Editorial:XDR-TB-a Global Threat. Lancet; 368:964.
  • 17
    Wright A., Bai G., Barrera L., Boulahbal F., Martín-Casabona N., Gilpin C., et al (2006) Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs–Worldwide, 2000–2004. Morbidity and Mortality Weekly Report (MMWR); 55:3015.
  • 18
    He X., Alian A., Stroud R., De Montellano P.R.O. (2006) Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J Med Chem;49:63086323.
  • 19
    Rai D., Johar M., Srivastav N.C., Manning T., Agrawal B., Kunimoto D.Y. et al. (2007) Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. J Med Chem;50:47664774.
  • 20
    Qiao C., Gupte A., Boshoff H.I., Wilson D.J., Bennett E.M., Somu R.V. et al. (2007) 5′-O-[(N-acyl)sulfamoyl]adenosines as antitubercular agents that inhibit MbtA: an adenylation enzyme required for siderophore biosynthesis of the mycobactins. J Med Chem;50:60806094.
  • 21
    Johar M., Manning T., Tse C., Desroches N., Agrawal B., Kunimoto D.Y. et al. (2007) Growth inhibition of Mycobacterium bovis, Mycobacterium tuberculosis and Mycobacterium avium in vitro: effect of 1-beta-D-2′-arabinofuranosyl and 1-(2′-deoxy-2′-fluoro-beta-D-2′-ribofuranosyl) pyrimidine nucleoside analogs. J Med Chem;50:36963705.
  • 22
    Van Daele I., Munier-Lehmann H., Froeyen M., Balzarini J., Van Calenbergh S. (2007) Rational design of 5′-thiourea-substituted alpha-thymidine analogues as thymidine monophosphate kinase inhibitors capable of inhibiting mycobacterial growth. J Med Chem;50:52815292.
  • 23
    Panda G., Parai M.K., Das S.K., Shagufta, Sinha M., Chaturvedi V. et al. (2007) Effect of substituents on diarylmethanes for antitubercular activity. Eur J Med Chem;42:410419.
  • 24
    Gupta R.A., Gupta A.K., Soni L.K., Kaskhedikar S.G. (2007) Rationalization of physicochemical characters of oxazolyl thiosemicarbazone analogs towards multi-drug resistant tuberculosis: a QSAR approach. Eur J Med Chem;42:11091116.
  • 25
    Ali M.A., Shaharyar M., Siddiqui A.A. (2007) Synthesis, structural activity relationship and anti-tubercular activity of novel pyrazoline derivatives. Eur J Med Chem;42:268275.
  • 26
    De Almeida M.V., Le Hyaric M., Amarante G.W., Silva Lourenco M.C., Lima Brandao M.L. (2007) Synthesis of amphiphilic galactopyranosyl diamines and amino alcohols as antitubercular agents. Eur J Med Chem;42:10761083.
  • 27
    Swamy B.N., Suma T.K., Rao G.V., Reddy G.C. (2007) Synthesis of isonicotinoylhydrazones from anacardic acid and their in vitro activity against Mycobacterium smegmatis. Eur J Med Chem;42:420424.
  • 28
    Shiradkar M., Suresh Kumar G.V., Dasari V., Tatikonda S., Akula K.C., Shah R. (2007) Clubbed triazoles: a novel approach to antitubercular drugs. Eur J Med Chem;42:807816.
  • 29
    McKee T.C., Covington C.D., Fuller R.W., Bokesch H.R., Young S., Cardellina I.J. et al. (1998) Pyranocoumarins from tropical species of the genus Calophyllum: a chemotaxonomic study of extracts in the National Cancer Institute collection. J Nat Prod;61:12521256.
  • 30
    Spino C., Dodier M., Sotheeswaran S. (1998) Anti-HIV coumarins from Calophyllum seed oil. Bioorg Med Chem Lett;8:34753478.
  • 31
    Dodia N., Shah A. (1999) Single step synthesis and antimicrobial, antitubercular screening of substituted2,4-dihydroquinolines. Ind J Heterocyl Chem;9:139142.
  • 32
    Dodia N., Shah A. (2000) Synthesis and antitubercular activity of some substituted 3-nitro and 3-bromo-4-hydroxy-2-quinolones. Ind J Hterocyl Chem;10:6970.
  • 33
    Desai B., Sureja D., Naliapara Y., Shah A., Saxena A.K. (2001) Synthesis and QSAR studies of 4-substitutedphenyl-2,6-dimethyl-3,5-bis-N-(substitutedphenyl)carbamoyl-1,4-dihydropyridines as potential antitubercular agents. Bioorg Med Chem;9:19931998.
  • 34
    Gaveriya H., Desai B., Vora V., Shah A. (2002) Synthesis and antitubercular activity studies of some unsymmetrical 1,4-dihydropyridines. Ind J Pharm Sci;64:5962.
  • 35
    Kharkar P.S., Desai B., Gaveria H., Varu B., Loriya R., Naliapara Y. et al. (2002) Three-dimensional quantitative structure-activity relationship of 1,4-dihydropyridines as antitubercular agents. J Med Chem;45:48584867.
  • 36
    Virsodia V., Pissurlenkar R.R., Manvar D., Dholakia C., Adlakha P., Shah A. et al. (2008) Synthesis, screening for antitubercular activity and 3D-QSAR studies of substituted N-phenyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxami des. Eur J Med Chem;43:21032115.
  • 37
    Virsodia V., Manvar A., Upadhyay K., Loriya R., Karia D., Jaggi M. et al. (2009) Synthesis of 1-(2,6-dichlorophenyl)-3-methylene-1,3-dihydroindol-2-one derivatives and in vitro anticancer evaluation against SW620 colon cancer cell line. Eur J Med Chem;44:13551362.
  • 38
    Manvar A., Malde A., Verma J., Virsodia V., Mishra A., Upadhyay K. et al. (2008) Synthesis, anti-tubercular activity and 3D-QSAR study of coumarin-4-acetic acid benzylidene hydrazides. Eur J Med Chem;43:23952403.
  • 39
    Roma G., Cinone N., Di Braccio M., Grossi G., Leoncini G., Signorello M.G. et al. (2000) Synthesis, antiplatelet activity and comparative molecular field analysis of substituted 2-amino-4H-pyrido[1,2-a]pyrimidin-4-ones, their congeners and isosteric analogues. Bioorg Med Chem;8:751768.
  • 40
    Roma G., Braccio M.D., Carrieri A., Grossi G., Leoncini G., Grazia Signorello M. et al. (2003) Coumarin, chromone, and 4(3H)-pyrimidinone novel bicyclic and tricyclic derivatives as antiplatelet agents: synthesis, biological evaluation, and comparative molecular field analysis. Bioorg Med Chem;11:123138.
  • 41
    Cramer R.D., Patterson D.E., Bunce J.D. (1988) Comparative molecular field analysis (CoMFA). 1 Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc;110:59595967.
  • 42
    Cramer R.D. 3rd, Patterson D.E., Bunce J.D. (1989) Recent advances in comparative molecular field analysis (CoMFA). Prog Clin Biol Res;291:161165.
  • 43
    Kellogg G.E., Semus S.F., Abraham D.J. (1991) HINT: a new method of empirical hydrophobic field calculation for CoMFA. J Comput-Aid Mol Des;5:545552.
  • 44
    Chavda M., Shah A., Bhatt S., Deo K., Kundu P. (2003) Antimicrobial screening and single step synthesis of some arylamino coumarins. Ind J Chem;42B:15021507.
  • 45
    Shah A.K., Bhatt N.S., Raval R.V., Thakor V.M. (1984) Synthesis of 4-hydroxycoumarins. Current Science;53:12411242.
  • 46
    Shah A., Naliapara Y., Sureja D., Motohashi N., Kurihara T., Kawase M. et al. (1998) Biological activity of 6,12-dihydro-1-benzopyrano [3,4-b][1,4] benzothiazin-6-ones. Anticancer Res;18:6163.
  • 47
    Shah A., Naliapara Y., Sureja D., Motohashi N., Kawase M., Miskolci C. et al. (1998) 6,12-Dihydro-1-benzopyrano [3, 4-b] [1, 4] benzothiazin-6-ones: Synthesis and MDR reversal in tumor cells. Anticancer Res;18:30013004.
  • 48
    Wold S., Johansson E., Cocchi M. (1993) PLS-partial least squares projections to latent structures in 3D-QSAR in drug design; theory methods and applications. In: KubinyiM.H., editor. PLS-partial least squares projections to latent structures in 3D-QSAR in drug design; theory methods and applications. The Netherlands: ESCOM Lieden; p. 523550.
  • 49
    Bush B.L., Nachbar R.B. Jr (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des;7:587619.
  • 50
    Richard D., Cramer R.D. III, Bunce J.D., Patterson D.E., Frank I.E. (1988) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct-Act Relat;7:1825.
  • 51
    Gunter B. (1994) Bootstrapping. Infect Control Hosp Epidemiol;15:543547.
  • 52
    Shao J. (1996) Bootstrap Model Selection. J Am Stat Assoc;91:655665.
  • 53
    Tropsha A., Gramatica P., Gombar V.K. (2003) The Importance of Being Earnest: validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models. QSAR Comb Sci;22:6977.
  • 54
    Rucker C., Rucker G., Meringer M. (2007) y-Randomization and its variants in QSPR/QSAR. J Chem Inf Model;47:23452357.
  • 55
    Manvar A.T., Pissurlenkar R.R., Virsodia V.R., Upadhyay K.D., Manvar D.R., Mishra A.K. et al. (2010) Synthesis, in vitro antitubercular activity and 3D-QSAR study of 1,4-dihydropyridines. Mol Divers;14:285305.
  • 56
    Lee S.K., Lee I.H., Kim H.J., Chang G.S., Chung J.E., No K.T. (2003) The PreADME approach: Web-based program for rapid prediction of physico-chemical, drug absorption and drug-like properties. Massachusetts, USA: Blackwell Publishing.
  • 57
    Zagorevskii V.A., Savelev V.L., Meshcheryakova L.M. (1970) On synthesis of 4-aminocoumarins and on mechanism of halogen substitution in 4- chlorocoumarin. Khim Geterotsikl Soed;8:10191023.